Merck awards €1.25 million to research projects through its 2017 Grant for Fertility Innovation (GFI)

MerckMerck, a leading science and technology company, today announced its commitment to award €1.25 million to research projects in the field of fertility, supporting the advancement of medical science through the Grant for Fertility Innovation (GFI) in 2017. Launched as the first of the Merck Grants for Innovation in 2009, Merck's GFI is providing encouragement for innovation and support for scientists to realize projects that could potentially lead to the next breakthrough in the fertility treatment area. This year, the GFI Award Ceremony included the announcement of the Merck Lifetime Achievement Award in Fertility Innovation.

To recognize Merck's belief in progress through innovation, the GFI awardees were revealed in a ceremony at the European Society of Human Reproduction and Embryology (ESHRE), currently taking place in Geneva, Switzerland. The winning projects truly reflect the global nature of the program, ranging from research in Italy to Brazil.

Professor Bruno Lunenfeld, a speaker at the GFI 2017 ceremony, was honored with the Merck Lifetime Achievement Award for his revolutionary work within the fertility field since 1954. At the ceremony he provided an overview on the discovery of human gonadotropins from postmenopausal urine.

"Professor Lunenfeld's pioneering achievements in the field of fertility are a huge inspiration to us at Merck. It is highly motivating to consider the breadth of his contributions. For more than 60 years now, his expertise and experience have greatly contributed to our efforts to improve the quality of patient care," said Belén Garijo, member of the Executive Board of Merck and CEO Healthcare, when presenting Professor Lunenfeld with the Merck Lifetime Achievement Award.

The research investments through the GFI is core to the innovation strategy of the biopharma business of Merck, and in the quest for increased success rates within fertility treatment. In this year's GFI, two winning projects were selected from 46 global proposals with the common goal of advancing the fertility field. The GFI was launched in 2009, and is dedicated to transforming innovative translational fertility research projects into actual solutions with the aim to improve fertility treatment outcomes. Merck proudly announced the 2017 GFI awardees during the ceremony:

  • Endometrial Notch pathway as a novel target for improving implantation efficiency; Luisa Campagnolo, PhD
  • Pharmacogenetic algorithm for individualized controlled ovarian stimulation (iCOS) in assisted reproductive technology cycles; Caio Parente Barbosa, MD, PhD, MS and Matheus Roque, MD

About the Grant for Fertility Innovation (GFI)
Merck announced the initiation of the GFI program in 2009 to support the advancement of science and innovative technologies in the fertility field. This grant is awarded every year to translational research projects that can potentially improve baby birth rate for the benefit of the patients. Each project is blinded and evaluated by a jury of experts according to five criteria: support to increase baby birth rate; innovative research; scientific rationale; feasibility and practical utility.

For further information about the GFI and how to apply for next year’s grants, please visit: www.grantforfertilityinnovation.com

About Merck
Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life - from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck generated sales of € 15.0 billion in 66 countries.

Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. The company holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

Most Popular Now

GSK reaches agreement with Novartis to acquire ful…

GlaxoSmithKline plc (LSE/NYSE: GSK) today announces that it has reached an agreement with Novartis for the buyout of Novartis' 36.5% stake in their Consumer Healthcare Jo...

Canadian neuroscientists say daily ibuprofen can p…

A Vancouver-based research team led by Canada's most cited neuroscientist, Dr. Patrick McGeer, has successfully carried out studies suggesting that, if started early enou...

First proof a synthesized antibiotic is capable of…

A "game changing" new antibiotic which is capable of killing superbugs has been successfully synthesised and used to treat an infection for the first time - and could lea...

Merck partners with Medisafe to help improve medic…

Merck, a leading science and technology company, today announced a new collaboration with US-based Medisafe to help its cardiometabolic patients better manage medication ...

Phase III data in The Lancet show Novartis siponim…

Novartis today announced that the full results from the Phase III EXPAND study of oral, once-daily siponimod (BAF312) in secondary progressive multiple sclerosis (SPMS) w...

Taking a standard prostate cancer drug with food b…

By taking a high-cost drug with a low-fat meal - instead of on an empty stomach, as prescribed - prostate cancer patients could decrease their daily dose, prevent digesti...

North and south cooperation to combat tuberculosis

Tuberculosis can be cured and could be eradicated. For this to happen, however, patients have to receive the right treatment. Researchers at the Makerere University and t...

Boehringer Ingelheim and OSE Immunotherapeutics an…

Boehringer Ingelheim and OSE Immunotherapeutics, a biotechnology company focused on the development of innovative immunotherapies, have announced a collaboration and excl...

New immunotherapy for lung cancer shows promise of…

In a groundbreaking development, results from a recent clinical trial to treat lung cancer show that a novel immunotherapy combination is surprisingly effective at contro...

Personalized tumor vaccine shows promise in pilot …

A new type of cancer vaccine has yielded promising results in an initial clinical trial conducted at the Perelman School of Medicine at the University of Pennsylvania and...

Lokelma approved in the EU for the treatment of ad…

AstraZeneca today announced that the European Commission has granted marketing authorisation for Lokelma (formerly ZS-9, sodium zirconium cyclosilicate) for the treatment...

New targeted therapy schedule could keep melanoma …

Skin melanoma, a particularly insidious cancer, accounts for the vast majority skin cancer deaths and is one of the most common cancers in people under 30. Treatment for ...